A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia

NCT07253584 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia

Interventions

DRUG: SAL003 140 mg
DRUG: Placebo

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.